Rheumatic Heart Disease Carries a Distinct Burden Across a Woman’s Life Course

Rheumatic heart disease does not unfold in a single clinical moment. In women, it can begin with the silent aftermath of untreated streptococcal infection in childhood, then reappear later as valvular dysfunction intersects with menstruation, pregnancy, childbirth, family caregiving, and aging. This review centers that trajectory and asks a practical question: how does a disease rooted in early-life infection become a lifelong cardiovascular burden that is shaped by sex, biology, and access to care?

Women with rheumatic heart disease often encounter the condition at the most vulnerable points in life, when symptoms can be misread, minimized, or absorbed into competing demands. Breathlessness, fatigue, palpitations, and reduced exercise tolerance may be dismissed as anemia, deconditioning, or the strain of daily work. When valvular disease is not recognized early, the consequences extend far beyond the heart itself. Progressive valve damage can limit schooling, employment, and pregnancy safety, and can complicate decisions that should otherwise be routine in chronic cardiovascular care.

Sex-Specific Vulnerabilities Shape Diagnosis, Treatment, and Outcomes

The review places women’s vulnerability at the center of rheumatic heart disease care rather than at the margins. That framing matters because sex differences in cardiovascular medicine are often driven less by the valve lesion itself than by the systems surrounding it: delayed recognition, unequal referral patterns, and fragmented follow-up. Rheumatic valvular disease in women also overlaps with reproductive health, making it impossible to separate cardiac management from obstetric planning.

Pregnancy is especially consequential. A stenotic or regurgitant valve that remains clinically manageable in everyday life can become dangerous when blood volume rises and cardiac output increases. Even without a specific procedural roadmap in hand, the bedside implication is direct: reproductive counseling, preconception assessment, and coordinated follow-up are not optional add-ons. They are part of basic risk reduction for women living with rheumatic heart disease.

Late presentation carries its own penalty. Once valve injury is established, treatment becomes more complex and more invasive, and the window for prevention has already narrowed. In that sense, the disease exposes a familiar weakness in cardiovascular care: the gap between early injury and the first decisive clinical encounter.

Prevention Has to Start Before Valve Damage Becomes Fixed

This review is framed around life-course strategies, and that choice reflects the biology of the disease. Rheumatic heart disease begins with immune-mediated injury after group A streptococcal infection, then evolves into chronic valvular deformation. Prevention therefore has to work at multiple levels: stopping streptococcal infection from progressing, identifying acute rheumatic fever early, and sustaining secondary prophylaxis long enough to prevent recurrent injury.

For women, those preventive layers must be reliable across adolescence and adulthood. A girl treated after her first episode of rheumatic fever may still face future interruptions in care if access changes during school transitions, migration, marriage, pregnancy, or caregiving responsibilities. Those disruptions are clinically meaningful because recurrent inflammatory injury is what turns a preventable condition into a permanent structural problem. Long-term adherence, continuity of records, and health-system follow-up are not administrative details; they are the mechanism by which preventable valve disease is either contained or allowed to advance.

A second practical issue is that prevention cannot stop at the patient level. Household crowding, social disadvantage, and barriers to timely treatment influence exposure and recurrence risk, especially in settings where rheumatic disease remains common. Women may also face a lower threshold for diagnostic delay when symptoms are normalized as part of reproductive life. The result is a double burden: a biologically progressive disease layered on top of social and gendered delay.

Maternal Care Must Be Integrated With Rheumatic Heart Disease Management

The review’s life-course lens naturally draws attention to maternal care. Women with rheumatic heart disease need cardiac assessment before conception when possible, and they need close surveillance during pregnancy and after delivery when hemodynamic stress is highest. A valve lesion that is stable in clinic can destabilize quickly under the circulatory demands of gestation, labor, and the postpartum period.

That makes multidisciplinary care essential. Cardiology, obstetrics, anesthesia, and primary care each hold part of the response, but none can manage the full risk alone. Even in settings where advanced interventions are limited, structured coordination can still reduce avoidable harm through symptom recognition, medication continuity, and planning for delivery in an appropriate setting. The challenge is not merely clinical competence; it is making sure women do not arrive in care only after the disease has already dictated the terms of pregnancy.

Why a Life-Course Strategy Is the Most Realistic Path Forward

A life-course framework fits rheumatic heart disease because the condition itself is cumulative. Early infection leads to acute rheumatic fever, recurrent immune injury leads to valve damage, and valve damage leads to chronic disability. In women, that sequence is repeatedly modified by access, reproduction, and social roles. A strategy that ignores any one of those layers will miss the patients most likely to be harmed.

The review points toward prevention and care that begin in childhood and remain active through adulthood. That includes better recognition of streptococcal illness, sustained prophylaxis after rheumatic fever, earlier diagnosis of valve disease, and reproductive counseling once structural heart disease is present. It also means designing services that do not disappear when a girl becomes a woman, becomes pregnant, or moves between health systems.

The clinical question left open by this kind of review is not whether rheumatic heart disease matters in women. It is how consistently health systems will identify risk early enough to prevent a lifelong valve disease from becoming a predictable part of female cardiovascular care.


Reporting by Dr. Aishwarya N., MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.